nodes	percent_of_prediction	percent_of_DWPC	metapath
Bezafibrate—PPARG—urinary bladder cancer	0.603	1	CbGaD
Bezafibrate—SLCO1B1—Methotrexate—urinary bladder cancer	0.0255	0.263	CbGbCtD
Bezafibrate—CYP3A4—Thiotepa—urinary bladder cancer	0.0245	0.252	CbGbCtD
Bezafibrate—CYP2C8—Fluorouracil—urinary bladder cancer	0.0196	0.202	CbGbCtD
Bezafibrate—CYP2C8—Etoposide—urinary bladder cancer	0.0164	0.168	CbGbCtD
Bezafibrate—CYP3A4—Etoposide—urinary bladder cancer	0.00663	0.0683	CbGbCtD
Bezafibrate—PPARD—prostate gland—urinary bladder cancer	0.00459	0.0685	CbGeAlD
Bezafibrate—CYP3A4—Doxorubicin—urinary bladder cancer	0.00452	0.0466	CbGbCtD
Bezafibrate—PPARA—prostate gland—urinary bladder cancer	0.00391	0.0584	CbGeAlD
Bezafibrate—PPARA—epithelium—urinary bladder cancer	0.00288	0.0429	CbGeAlD
Bezafibrate—PPARA—smooth muscle tissue—urinary bladder cancer	0.00277	0.0413	CbGeAlD
Bezafibrate—PPARG—Teniposide—Etoposide—urinary bladder cancer	0.00274	1	CbGdCrCtD
Bezafibrate—CYP3A4—urine—urinary bladder cancer	0.00268	0.0399	CbGeAlD
Bezafibrate—PPARA—renal system—urinary bladder cancer	0.00267	0.0398	CbGeAlD
Bezafibrate—HMGCR—prostate gland—urinary bladder cancer	0.0026	0.0389	CbGeAlD
Bezafibrate—PPARD—female reproductive system—urinary bladder cancer	0.00251	0.0374	CbGeAlD
Bezafibrate—PPARD—vagina—urinary bladder cancer	0.00227	0.0338	CbGeAlD
Bezafibrate—HMGCR—seminal vesicle—urinary bladder cancer	0.0022	0.0329	CbGeAlD
Bezafibrate—PPARG—prostate gland—urinary bladder cancer	0.00215	0.0321	CbGeAlD
Bezafibrate—PPARA—female reproductive system—urinary bladder cancer	0.00214	0.0319	CbGeAlD
Bezafibrate—HMGCR—epithelium—urinary bladder cancer	0.00191	0.0286	CbGeAlD
Bezafibrate—HMGCR—smooth muscle tissue—urinary bladder cancer	0.00184	0.0275	CbGeAlD
Bezafibrate—HMGCR—renal system—urinary bladder cancer	0.00178	0.0265	CbGeAlD
Bezafibrate—HMGCR—urethra—urinary bladder cancer	0.00174	0.026	CbGeAlD
Bezafibrate—SLCO1B1—renal system—urinary bladder cancer	0.0017	0.0254	CbGeAlD
Bezafibrate—PPARG—epithelium—urinary bladder cancer	0.00158	0.0236	CbGeAlD
Bezafibrate—PPARG—smooth muscle tissue—urinary bladder cancer	0.00152	0.0227	CbGeAlD
Bezafibrate—Indomethacin—UGT2B7—urinary bladder cancer	0.00148	0.296	CrCbGaD
Bezafibrate—PPARG—renal system—urinary bladder cancer	0.00147	0.0219	CbGeAlD
Bezafibrate—PPARD—lymph node—urinary bladder cancer	0.00147	0.0219	CbGeAlD
Bezafibrate—PPARG—urethra—urinary bladder cancer	0.00144	0.0215	CbGeAlD
Bezafibrate—HMGCR—female reproductive system—urinary bladder cancer	0.00142	0.0212	CbGeAlD
Bezafibrate—SLCO1B1—female reproductive system—urinary bladder cancer	0.00136	0.0203	CbGeAlD
Bezafibrate—Balsalazide—PPARG—urinary bladder cancer	0.00131	0.262	CrCbGaD
Bezafibrate—HMGCR—vagina—urinary bladder cancer	0.00129	0.0192	CbGeAlD
Bezafibrate—PPARA—lymph node—urinary bladder cancer	0.00125	0.0186	CbGeAlD
Bezafibrate—PPARG—female reproductive system—urinary bladder cancer	0.00117	0.0175	CbGeAlD
Bezafibrate—PPARG—vagina—urinary bladder cancer	0.00106	0.0158	CbGeAlD
Bezafibrate—CYP2C8—renal system—urinary bladder cancer	0.000967	0.0144	CbGeAlD
Bezafibrate—CYP1A1—epithelium—urinary bladder cancer	0.000962	0.0144	CbGeAlD
Bezafibrate—CYP1A1—renal system—urinary bladder cancer	0.000893	0.0133	CbGeAlD
Bezafibrate—CYP1A1—urethra—urinary bladder cancer	0.000877	0.0131	CbGeAlD
Bezafibrate—Indomethacin—CXCL8—urinary bladder cancer	0.000839	0.167	CrCbGaD
Bezafibrate—HMGCR—lymph node—urinary bladder cancer	0.000832	0.0124	CbGeAlD
Bezafibrate—CYP2C8—female reproductive system—urinary bladder cancer	0.000774	0.0116	CbGeAlD
Bezafibrate—CYP1A1—female reproductive system—urinary bladder cancer	0.000715	0.0107	CbGeAlD
Bezafibrate—CYP2C8—vagina—urinary bladder cancer	0.0007	0.0104	CbGeAlD
Bezafibrate—PPARG—lymph node—urinary bladder cancer	0.000687	0.0103	CbGeAlD
Bezafibrate—CYP3A4—renal system—urinary bladder cancer	0.000655	0.00977	CbGeAlD
Bezafibrate—CYP1A1—vagina—urinary bladder cancer	0.000647	0.00964	CbGeAlD
Bezafibrate—Indomethacin—PPARG—urinary bladder cancer	0.000579	0.116	CrCbGaD
Bezafibrate—Balsalazide—PTGS2—urinary bladder cancer	0.000555	0.111	CrCbGaD
Bezafibrate—CYP3A4—female reproductive system—urinary bladder cancer	0.000525	0.00783	CbGeAlD
Bezafibrate—Diarrhoea—Mitomycin—urinary bladder cancer	0.000494	0.00477	CcSEcCtD
Bezafibrate—Photosensitivity reaction—Fluorouracil—urinary bladder cancer	0.000482	0.00465	CcSEcCtD
Bezafibrate—Cramp muscle—Etoposide—urinary bladder cancer	0.000478	0.00461	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.000478	0.00461	CcSEcCtD
Bezafibrate—Dizziness—Mitomycin—urinary bladder cancer	0.000478	0.00461	CcSEcCtD
Bezafibrate—Pancytopenia—Cisplatin—urinary bladder cancer	0.000476	0.00459	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.000475	0.00458	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Gemcitabine—urinary bladder cancer	0.000472	0.00456	CcSEcCtD
Bezafibrate—Myocardial infarction—Gemcitabine—urinary bladder cancer	0.00047	0.00453	CcSEcCtD
Bezafibrate—Alanine aminotransferase increased—Etoposide—urinary bladder cancer	0.000468	0.00452	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Fluorouracil—urinary bladder cancer	0.000464	0.00448	CcSEcCtD
Bezafibrate—Myocardial infarction—Fluorouracil—urinary bladder cancer	0.000462	0.00446	CcSEcCtD
Bezafibrate—Rash—Mitomycin—urinary bladder cancer	0.000456	0.00439	CcSEcCtD
Bezafibrate—Dermatitis—Mitomycin—urinary bladder cancer	0.000455	0.00439	CcSEcCtD
Bezafibrate—Headache—Mitomycin—urinary bladder cancer	0.000453	0.00437	CcSEcCtD
Bezafibrate—Alopecia—Thiotepa—urinary bladder cancer	0.000452	0.00436	CcSEcCtD
Bezafibrate—Erythema—Thiotepa—urinary bladder cancer	0.000445	0.00429	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Cisplatin—urinary bladder cancer	0.00044	0.00425	CcSEcCtD
Bezafibrate—Myocardial infarction—Cisplatin—urinary bladder cancer	0.000438	0.00422	CcSEcCtD
Bezafibrate—Pancytopenia—Etoposide—urinary bladder cancer	0.000436	0.0042	CcSEcCtD
Bezafibrate—Nausea—Mitomycin—urinary bladder cancer	0.000429	0.00414	CcSEcCtD
Bezafibrate—Pharyngitis—Gemcitabine—urinary bladder cancer	0.000427	0.00412	CcSEcCtD
Bezafibrate—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.000425	0.0041	CcSEcCtD
Bezafibrate—Urethral disorder—Gemcitabine—urinary bladder cancer	0.000422	0.00407	CcSEcCtD
Bezafibrate—Pharyngitis—Fluorouracil—urinary bladder cancer	0.00042	0.00405	CcSEcCtD
Bezafibrate—CYP1A1—lymph node—urinary bladder cancer	0.000418	0.00624	CbGeAlD
Bezafibrate—Anaemia—Thiotepa—urinary bladder cancer	0.000411	0.00397	CcSEcCtD
Bezafibrate—Phosphatase alkaline increased—Epirubicin—urinary bladder cancer	0.00041	0.00396	CcSEcCtD
Bezafibrate—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000407	0.00392	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.000406	0.00391	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.000403	0.00389	CcSEcCtD
Bezafibrate—Myocardial infarction—Etoposide—urinary bladder cancer	0.000401	0.00387	CcSEcCtD
Bezafibrate—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000396	0.00382	CcSEcCtD
Bezafibrate—Urethral disorder—Cisplatin—urinary bladder cancer	0.000393	0.00379	CcSEcCtD
Bezafibrate—Alopecia—Gemcitabine—urinary bladder cancer	0.00038	0.00367	CcSEcCtD
Bezafibrate—Phosphatase alkaline increased—Doxorubicin—urinary bladder cancer	0.000379	0.00366	CcSEcCtD
Bezafibrate—Myalgia—Thiotepa—urinary bladder cancer	0.000379	0.00366	CcSEcCtD
Bezafibrate—Erythema—Gemcitabine—urinary bladder cancer	0.000375	0.00361	CcSEcCtD
Bezafibrate—Alopecia—Fluorouracil—urinary bladder cancer	0.000374	0.00361	CcSEcCtD
Bezafibrate—Erythema—Fluorouracil—urinary bladder cancer	0.000368	0.00355	CcSEcCtD
Bezafibrate—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000363	0.0035	CcSEcCtD
Bezafibrate—Photosensitivity—Methotrexate—urinary bladder cancer	0.000362	0.00349	CcSEcCtD
Bezafibrate—Infection—Thiotepa—urinary bladder cancer	0.000361	0.00348	CcSEcCtD
Bezafibrate—Urethral disorder—Etoposide—urinary bladder cancer	0.00036	0.00347	CcSEcCtD
Bezafibrate—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000356	0.00343	CcSEcCtD
Bezafibrate—Alopecia—Cisplatin—urinary bladder cancer	0.000354	0.00342	CcSEcCtD
Bezafibrate—Erythema—Cisplatin—urinary bladder cancer	0.000349	0.00337	CcSEcCtD
Bezafibrate—Erythema multiforme—Etoposide—urinary bladder cancer	0.000347	0.00335	CcSEcCtD
Bezafibrate—Anaemia—Gemcitabine—urinary bladder cancer	0.000346	0.00334	CcSEcCtD
Bezafibrate—Renal failure acute—Methotrexate—urinary bladder cancer	0.000345	0.00332	CcSEcCtD
Bezafibrate—Flatulence—Cisplatin—urinary bladder cancer	0.000344	0.00332	CcSEcCtD
Bezafibrate—Blood alkaline phosphatase increased—Epirubicin—urinary bladder cancer	0.000342	0.0033	CcSEcCtD
Bezafibrate—Anaemia—Fluorouracil—urinary bladder cancer	0.00034	0.00328	CcSEcCtD
Bezafibrate—Photosensitivity—Epirubicin—urinary bladder cancer	0.000339	0.00327	CcSEcCtD
Bezafibrate—Muscle spasms—Cisplatin—urinary bladder cancer	0.000336	0.00324	CcSEcCtD
Bezafibrate—Vascular purpura—Epirubicin—urinary bladder cancer	0.000333	0.00321	CcSEcCtD
Bezafibrate—Eczema—Epirubicin—urinary bladder cancer	0.000331	0.0032	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000331	0.00319	CcSEcCtD
Bezafibrate—Alopecia—Etoposide—urinary bladder cancer	0.000325	0.00313	CcSEcCtD
Bezafibrate—Anaemia—Cisplatin—urinary bladder cancer	0.000323	0.00311	CcSEcCtD
Bezafibrate—Renal failure acute—Epirubicin—urinary bladder cancer	0.000322	0.00311	CcSEcCtD
Bezafibrate—Dyspepsia—Thiotepa—urinary bladder cancer	0.00032	0.00309	CcSEcCtD
Bezafibrate—Myalgia—Gemcitabine—urinary bladder cancer	0.000319	0.00308	CcSEcCtD
Bezafibrate—Blood alkaline phosphatase increased—Doxorubicin—urinary bladder cancer	0.000317	0.00305	CcSEcCtD
Bezafibrate—Photosensitivity—Doxorubicin—urinary bladder cancer	0.000314	0.00303	CcSEcCtD
Bezafibrate—Myalgia—Fluorouracil—urinary bladder cancer	0.000313	0.00302	CcSEcCtD
Bezafibrate—Pain—Thiotepa—urinary bladder cancer	0.000311	0.003	CcSEcCtD
Bezafibrate—Constipation—Thiotepa—urinary bladder cancer	0.000311	0.003	CcSEcCtD
Bezafibrate—Purpura—Epirubicin—urinary bladder cancer	0.000309	0.00298	CcSEcCtD
Bezafibrate—Vascular purpura—Doxorubicin—urinary bladder cancer	0.000308	0.00297	CcSEcCtD
Bezafibrate—Muscle spasms—Etoposide—urinary bladder cancer	0.000307	0.00297	CcSEcCtD
Bezafibrate—Eczema—Doxorubicin—urinary bladder cancer	0.000306	0.00296	CcSEcCtD
Bezafibrate—Infection—Gemcitabine—urinary bladder cancer	0.000304	0.00293	CcSEcCtD
Bezafibrate—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000299	0.00289	CcSEcCtD
Bezafibrate—Infection—Fluorouracil—urinary bladder cancer	0.000299	0.00288	CcSEcCtD
Bezafibrate—Renal failure acute—Doxorubicin—urinary bladder cancer	0.000298	0.00288	CcSEcCtD
Bezafibrate—Myalgia—Cisplatin—urinary bladder cancer	0.000297	0.00287	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000297	0.00287	CcSEcCtD
Bezafibrate—Anaemia—Etoposide—urinary bladder cancer	0.000296	0.00285	CcSEcCtD
Bezafibrate—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000294	0.00284	CcSEcCtD
Bezafibrate—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.000294	0.00283	CcSEcCtD
Bezafibrate—Migraine—Epirubicin—urinary bladder cancer	0.000293	0.00283	CcSEcCtD
Bezafibrate—Urticaria—Thiotepa—urinary bladder cancer	0.000289	0.00278	CcSEcCtD
Bezafibrate—Abdominal pain—Thiotepa—urinary bladder cancer	0.000287	0.00277	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.000286	0.00276	CcSEcCtD
Bezafibrate—Purpura—Doxorubicin—urinary bladder cancer	0.000286	0.00276	CcSEcCtD
Bezafibrate—Infection—Cisplatin—urinary bladder cancer	0.000283	0.00273	CcSEcCtD
Bezafibrate—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000279	0.00269	CcSEcCtD
Bezafibrate—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000279	0.00269	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000278	0.00269	CcSEcCtD
Bezafibrate—Insomnia—Gemcitabine—urinary bladder cancer	0.000276	0.00267	CcSEcCtD
Bezafibrate—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.000275	0.00265	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000274	0.00264	CcSEcCtD
Bezafibrate—Insomnia—Fluorouracil—urinary bladder cancer	0.000272	0.00262	CcSEcCtD
Bezafibrate—Migraine—Doxorubicin—urinary bladder cancer	0.000271	0.00262	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000268	0.00259	CcSEcCtD
Bezafibrate—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000268	0.00259	CcSEcCtD
Bezafibrate—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000268	0.00258	CcSEcCtD
Bezafibrate—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000265	0.00255	CcSEcCtD
Bezafibrate—Gastritis—Epirubicin—urinary bladder cancer	0.000263	0.00254	CcSEcCtD
Bezafibrate—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000263	0.00253	CcSEcCtD
Bezafibrate—Muscular weakness—Epirubicin—urinary bladder cancer	0.000263	0.00253	CcSEcCtD
Bezafibrate—Constipation—Gemcitabine—urinary bladder cancer	0.000261	0.00252	CcSEcCtD
Bezafibrate—Pain—Gemcitabine—urinary bladder cancer	0.000261	0.00252	CcSEcCtD
Bezafibrate—Pancytopenia—Methotrexate—urinary bladder cancer	0.000261	0.00252	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00026	0.0025	CcSEcCtD
Bezafibrate—Infection—Etoposide—urinary bladder cancer	0.000259	0.0025	CcSEcCtD
Bezafibrate—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000258	0.00249	CcSEcCtD
Bezafibrate—Influenza—Epirubicin—urinary bladder cancer	0.000257	0.00248	CcSEcCtD
Bezafibrate—Pruritus—Thiotepa—urinary bladder cancer	0.000257	0.00248	CcSEcCtD
Bezafibrate—Pain—Fluorouracil—urinary bladder cancer	0.000257	0.00248	CcSEcCtD
Bezafibrate—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000256	0.00247	CcSEcCtD
Bezafibrate—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000254	0.00245	CcSEcCtD
Bezafibrate—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000253	0.00244	CcSEcCtD
Bezafibrate—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000251	0.00242	CcSEcCtD
Bezafibrate—Diarrhoea—Thiotepa—urinary bladder cancer	0.000249	0.0024	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000248	0.00239	CcSEcCtD
Bezafibrate—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000248	0.00239	CcSEcCtD
Bezafibrate—Bronchitis—Epirubicin—urinary bladder cancer	0.000247	0.00239	CcSEcCtD
Bezafibrate—Indomethacin—PTGS2—urinary bladder cancer	0.000245	0.0488	CrCbGaD
Bezafibrate—Pancytopenia—Epirubicin—urinary bladder cancer	0.000244	0.00236	CcSEcCtD
Bezafibrate—Gastritis—Doxorubicin—urinary bladder cancer	0.000244	0.00235	CcSEcCtD
Bezafibrate—Pain—Cisplatin—urinary bladder cancer	0.000244	0.00235	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000243	0.00234	CcSEcCtD
Bezafibrate—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000243	0.00234	CcSEcCtD
Bezafibrate—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000243	0.00234	CcSEcCtD
Bezafibrate—Dizziness—Thiotepa—urinary bladder cancer	0.00024	0.00232	CcSEcCtD
Bezafibrate—Urticaria—Fluorouracil—urinary bladder cancer	0.000239	0.0023	CcSEcCtD
Bezafibrate—Influenza—Doxorubicin—urinary bladder cancer	0.000238	0.0023	CcSEcCtD
Bezafibrate—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000235	0.00227	CcSEcCtD
Bezafibrate—Rash—Thiotepa—urinary bladder cancer	0.000229	0.00221	CcSEcCtD
Bezafibrate—Bronchitis—Doxorubicin—urinary bladder cancer	0.000229	0.00221	CcSEcCtD
Bezafibrate—Dermatitis—Thiotepa—urinary bladder cancer	0.000229	0.00221	CcSEcCtD
Bezafibrate—Headache—Thiotepa—urinary bladder cancer	0.000228	0.0022	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000227	0.00219	CcSEcCtD
Bezafibrate—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000226	0.00218	CcSEcCtD
Bezafibrate—Pain—Etoposide—urinary bladder cancer	0.000223	0.00215	CcSEcCtD
Bezafibrate—Constipation—Etoposide—urinary bladder cancer	0.000223	0.00215	CcSEcCtD
Bezafibrate—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000221	0.00214	CcSEcCtD
Bezafibrate—Pharyngitis—Methotrexate—urinary bladder cancer	0.000218	0.00211	CcSEcCtD
Bezafibrate—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000217	0.0021	CcSEcCtD
Bezafibrate—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000217	0.0021	CcSEcCtD
Bezafibrate—Pruritus—Gemcitabine—urinary bladder cancer	0.000216	0.00209	CcSEcCtD
Bezafibrate—Nausea—Thiotepa—urinary bladder cancer	0.000216	0.00208	CcSEcCtD
Bezafibrate—Urethral disorder—Methotrexate—urinary bladder cancer	0.000216	0.00208	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000213	0.00206	CcSEcCtD
Bezafibrate—Pruritus—Fluorouracil—urinary bladder cancer	0.000213	0.00205	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00021	0.00203	CcSEcCtD
Bezafibrate—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00021	0.00202	CcSEcCtD
Bezafibrate—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000209	0.00202	CcSEcCtD
Bezafibrate—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000208	0.00201	CcSEcCtD
Bezafibrate—Urticaria—Etoposide—urinary bladder cancer	0.000207	0.002	CcSEcCtD
Bezafibrate—Abdominal pain—Etoposide—urinary bladder cancer	0.000206	0.00199	CcSEcCtD
Bezafibrate—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000206	0.00198	CcSEcCtD
Bezafibrate—Pharyngitis—Epirubicin—urinary bladder cancer	0.000204	0.00197	CcSEcCtD
Bezafibrate—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000203	0.00196	CcSEcCtD
Bezafibrate—Urethral disorder—Epirubicin—urinary bladder cancer	0.000202	0.00195	CcSEcCtD
Bezafibrate—Dizziness—Fluorouracil—urinary bladder cancer	0.000199	0.00192	CcSEcCtD
Bezafibrate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000195	0.00188	CcSEcCtD
Bezafibrate—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000195	0.00188	CcSEcCtD
Bezafibrate—Alopecia—Methotrexate—urinary bladder cancer	0.000194	0.00188	CcSEcCtD
Bezafibrate—Rash—Gemcitabine—urinary bladder cancer	0.000193	0.00186	CcSEcCtD
Bezafibrate—Dermatitis—Gemcitabine—urinary bladder cancer	0.000193	0.00186	CcSEcCtD
Bezafibrate—Hypersensitivity—Etoposide—urinary bladder cancer	0.000192	0.00186	CcSEcCtD
Bezafibrate—Erythema—Methotrexate—urinary bladder cancer	0.000192	0.00185	CcSEcCtD
Bezafibrate—Headache—Gemcitabine—urinary bladder cancer	0.000191	0.00185	CcSEcCtD
Bezafibrate—Rash—Fluorouracil—urinary bladder cancer	0.000189	0.00183	CcSEcCtD
Bezafibrate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000189	0.00183	CcSEcCtD
Bezafibrate—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000189	0.00182	CcSEcCtD
Bezafibrate—Headache—Fluorouracil—urinary bladder cancer	0.000188	0.00182	CcSEcCtD
Bezafibrate—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000188	0.00182	CcSEcCtD
Bezafibrate—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000187	0.0018	CcSEcCtD
Bezafibrate—Pruritus—Etoposide—urinary bladder cancer	0.000185	0.00178	CcSEcCtD
Bezafibrate—Alopecia—Epirubicin—urinary bladder cancer	0.000182	0.00176	CcSEcCtD
Bezafibrate—Nausea—Gemcitabine—urinary bladder cancer	0.000182	0.00175	CcSEcCtD
Bezafibrate—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00018	0.00174	CcSEcCtD
Bezafibrate—Rash—Cisplatin—urinary bladder cancer	0.00018	0.00173	CcSEcCtD
Bezafibrate—Dermatitis—Cisplatin—urinary bladder cancer	0.000179	0.00173	CcSEcCtD
Bezafibrate—Erythema—Epirubicin—urinary bladder cancer	0.000179	0.00173	CcSEcCtD
Bezafibrate—Diarrhoea—Etoposide—urinary bladder cancer	0.000179	0.00172	CcSEcCtD
Bezafibrate—Nausea—Fluorouracil—urinary bladder cancer	0.000179	0.00172	CcSEcCtD
Bezafibrate—Anaemia—Methotrexate—urinary bladder cancer	0.000177	0.00171	CcSEcCtD
Bezafibrate—Flatulence—Epirubicin—urinary bladder cancer	0.000177	0.0017	CcSEcCtD
Bezafibrate—Dizziness—Etoposide—urinary bladder cancer	0.000173	0.00166	CcSEcCtD
Bezafibrate—Muscle spasms—Epirubicin—urinary bladder cancer	0.000172	0.00166	CcSEcCtD
Bezafibrate—Nausea—Cisplatin—urinary bladder cancer	0.000169	0.00163	CcSEcCtD
Bezafibrate—Alopecia—Doxorubicin—urinary bladder cancer	0.000168	0.00162	CcSEcCtD
Bezafibrate—Erythema—Doxorubicin—urinary bladder cancer	0.000166	0.0016	CcSEcCtD
Bezafibrate—Anaemia—Epirubicin—urinary bladder cancer	0.000166	0.0016	CcSEcCtD
Bezafibrate—Rash—Etoposide—urinary bladder cancer	0.000165	0.00159	CcSEcCtD
Bezafibrate—Dermatitis—Etoposide—urinary bladder cancer	0.000164	0.00159	CcSEcCtD
Bezafibrate—Headache—Etoposide—urinary bladder cancer	0.000164	0.00158	CcSEcCtD
Bezafibrate—Flatulence—Doxorubicin—urinary bladder cancer	0.000163	0.00158	CcSEcCtD
Bezafibrate—Myalgia—Methotrexate—urinary bladder cancer	0.000163	0.00157	CcSEcCtD
Bezafibrate—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000159	0.00154	CcSEcCtD
Bezafibrate—Infection—Methotrexate—urinary bladder cancer	0.000155	0.0015	CcSEcCtD
Bezafibrate—Nausea—Etoposide—urinary bladder cancer	0.000155	0.0015	CcSEcCtD
Bezafibrate—Anaemia—Doxorubicin—urinary bladder cancer	0.000153	0.00148	CcSEcCtD
Bezafibrate—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000153	0.00148	CcSEcCtD
Bezafibrate—Myalgia—Epirubicin—urinary bladder cancer	0.000153	0.00147	CcSEcCtD
Bezafibrate—Infection—Epirubicin—urinary bladder cancer	0.000145	0.0014	CcSEcCtD
Bezafibrate—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000143	0.00138	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000142	0.00137	CcSEcCtD
Bezafibrate—Insomnia—Methotrexate—urinary bladder cancer	0.000141	0.00136	CcSEcCtD
Bezafibrate—Myalgia—Doxorubicin—urinary bladder cancer	0.000141	0.00136	CcSEcCtD
Bezafibrate—Dyspepsia—Methotrexate—urinary bladder cancer	0.000138	0.00133	CcSEcCtD
Bezafibrate—Infection—Doxorubicin—urinary bladder cancer	0.000134	0.0013	CcSEcCtD
Bezafibrate—Pain—Methotrexate—urinary bladder cancer	0.000134	0.00129	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000133	0.00129	CcSEcCtD
Bezafibrate—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000133	0.00128	CcSEcCtD
Bezafibrate—Insomnia—Epirubicin—urinary bladder cancer	0.000132	0.00128	CcSEcCtD
Bezafibrate—Dyspepsia—Epirubicin—urinary bladder cancer	0.000129	0.00124	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000128	0.00123	CcSEcCtD
Bezafibrate—Constipation—Epirubicin—urinary bladder cancer	0.000125	0.00121	CcSEcCtD
Bezafibrate—Pain—Epirubicin—urinary bladder cancer	0.000125	0.00121	CcSEcCtD
Bezafibrate—Urticaria—Methotrexate—urinary bladder cancer	0.000124	0.0012	CcSEcCtD
Bezafibrate—Abdominal pain—Methotrexate—urinary bladder cancer	0.000124	0.00119	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000123	0.00119	CcSEcCtD
Bezafibrate—Insomnia—Doxorubicin—urinary bladder cancer	0.000122	0.00118	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00012	0.00115	CcSEcCtD
Bezafibrate—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000119	0.00115	CcSEcCtD
Bezafibrate—Urticaria—Epirubicin—urinary bladder cancer	0.000116	0.00112	CcSEcCtD
Bezafibrate—Constipation—Doxorubicin—urinary bladder cancer	0.000116	0.00112	CcSEcCtD
Bezafibrate—Pain—Doxorubicin—urinary bladder cancer	0.000116	0.00112	CcSEcCtD
Bezafibrate—Abdominal pain—Epirubicin—urinary bladder cancer	0.000116	0.00112	CcSEcCtD
Bezafibrate—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000115	0.00111	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000111	0.00107	CcSEcCtD
Bezafibrate—Pruritus—Methotrexate—urinary bladder cancer	0.000111	0.00107	CcSEcCtD
Bezafibrate—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000108	0.00104	CcSEcCtD
Bezafibrate—Urticaria—Doxorubicin—urinary bladder cancer	0.000108	0.00104	CcSEcCtD
Bezafibrate—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000107	0.00103	CcSEcCtD
Bezafibrate—Diarrhoea—Methotrexate—urinary bladder cancer	0.000107	0.00103	CcSEcCtD
Bezafibrate—Pruritus—Epirubicin—urinary bladder cancer	0.000104	0.000999	CcSEcCtD
Bezafibrate—Dizziness—Methotrexate—urinary bladder cancer	0.000103	0.000997	CcSEcCtD
Bezafibrate—Diarrhoea—Epirubicin—urinary bladder cancer	0.0001	0.000966	CcSEcCtD
Bezafibrate—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.97e-05	0.000962	CcSEcCtD
Bezafibrate—Rash—Methotrexate—urinary bladder cancer	9.86e-05	0.000951	CcSEcCtD
Bezafibrate—Dermatitis—Methotrexate—urinary bladder cancer	9.85e-05	0.00095	CcSEcCtD
Bezafibrate—Headache—Methotrexate—urinary bladder cancer	9.79e-05	0.000945	CcSEcCtD
Bezafibrate—Dizziness—Epirubicin—urinary bladder cancer	9.67e-05	0.000933	CcSEcCtD
Bezafibrate—Pruritus—Doxorubicin—urinary bladder cancer	9.58e-05	0.000924	CcSEcCtD
Bezafibrate—Nausea—Methotrexate—urinary bladder cancer	9.29e-05	0.000896	CcSEcCtD
Bezafibrate—Diarrhoea—Doxorubicin—urinary bladder cancer	9.26e-05	0.000894	CcSEcCtD
Bezafibrate—Rash—Epirubicin—urinary bladder cancer	9.22e-05	0.00089	CcSEcCtD
Bezafibrate—Dermatitis—Epirubicin—urinary bladder cancer	9.22e-05	0.000889	CcSEcCtD
Bezafibrate—Headache—Epirubicin—urinary bladder cancer	9.17e-05	0.000884	CcSEcCtD
Bezafibrate—Dizziness—Doxorubicin—urinary bladder cancer	8.95e-05	0.000864	CcSEcCtD
Bezafibrate—Nausea—Epirubicin—urinary bladder cancer	8.69e-05	0.000838	CcSEcCtD
Bezafibrate—Rash—Doxorubicin—urinary bladder cancer	8.54e-05	0.000823	CcSEcCtD
Bezafibrate—Dermatitis—Doxorubicin—urinary bladder cancer	8.53e-05	0.000823	CcSEcCtD
Bezafibrate—Headache—Doxorubicin—urinary bladder cancer	8.48e-05	0.000818	CcSEcCtD
Bezafibrate—Nausea—Doxorubicin—urinary bladder cancer	8.04e-05	0.000776	CcSEcCtD
Bezafibrate—PPARA—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.46e-05	0.000448	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.46e-05	0.000448	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—TYMP—urinary bladder cancer	5.44e-05	0.000447	CbGpPWpGaD
Bezafibrate—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	5.42e-05	0.000445	CbGpPWpGaD
Bezafibrate—PPARD—Gene Expression—ERCC2—urinary bladder cancer	5.38e-05	0.000442	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—PRSS3—urinary bladder cancer	5.36e-05	0.00044	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—GSTT1—urinary bladder cancer	5.32e-05	0.000437	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—RHOA—urinary bladder cancer	5.31e-05	0.000436	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.24e-05	0.000431	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.23e-05	0.000429	CbGpPWpGaD
Bezafibrate—PPARG—Generic Transcription Pathway—ESR1—urinary bladder cancer	5.1e-05	0.000419	CbGpPWpGaD
Bezafibrate—PPARA—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.99e-05	0.000409	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—NAT2—urinary bladder cancer	4.92e-05	0.000404	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—ERBB2—urinary bladder cancer	4.92e-05	0.000404	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.91e-05	0.000404	CbGpPWpGaD
Bezafibrate—PPARD—Generic Transcription Pathway—MYC—urinary bladder cancer	4.86e-05	0.000399	CbGpPWpGaD
Bezafibrate—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	4.85e-05	0.000398	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—GSTP1—urinary bladder cancer	4.84e-05	0.000398	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—NQO1—urinary bladder cancer	4.84e-05	0.000397	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—CDK4—urinary bladder cancer	4.82e-05	0.000396	CbGpPWpGaD
Bezafibrate—CYP1A1—PPARA activates gene expression—EP300—urinary bladder cancer	4.7e-05	0.000386	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.69e-05	0.000386	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.69e-05	0.000385	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—GSTZ1—urinary bladder cancer	4.68e-05	0.000384	CbGpPWpGaD
Bezafibrate—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	4.66e-05	0.000382	CbGpPWpGaD
Bezafibrate—PPARG—Gene Expression—SMC1A—urinary bladder cancer	4.65e-05	0.000382	CbGpPWpGaD
Bezafibrate—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	4.6e-05	0.000378	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—TYMS—urinary bladder cancer	4.5e-05	0.00037	CbGpPWpGaD
Bezafibrate—PPARD—Gene Expression—ESR1—urinary bladder cancer	4.5e-05	0.000369	CbGpPWpGaD
Bezafibrate—PPARG—Generic Transcription Pathway—CREBBP—urinary bladder cancer	4.47e-05	0.000367	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—GSTM1—urinary bladder cancer	4.45e-05	0.000366	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—NCOR1—urinary bladder cancer	4.45e-05	0.000366	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—GSTO2—urinary bladder cancer	4.43e-05	0.000364	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—NAT1—urinary bladder cancer	4.43e-05	0.000364	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—NQO1—urinary bladder cancer	4.43e-05	0.000363	CbGpPWpGaD
Bezafibrate—PPARA—Gene Expression—NCOR1—urinary bladder cancer	4.36e-05	0.000358	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.36e-05	0.000358	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.3e-05	0.000353	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.29e-05	0.000353	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	4.29e-05	0.000352	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—TYMP—urinary bladder cancer	4.29e-05	0.000352	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—GPX1—urinary bladder cancer	4.26e-05	0.00035	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—RRM2—urinary bladder cancer	4.25e-05	0.000349	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—MMP9—urinary bladder cancer	4.22e-05	0.000346	CbGpPWpGaD
Bezafibrate—PPARG—Circadian rythm related genes—TP53—urinary bladder cancer	4.21e-05	0.000346	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—CREBBP—urinary bladder cancer	4.21e-05	0.000346	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—ERCC2—urinary bladder cancer	4.19e-05	0.000344	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.12e-05	0.000338	CbGpPWpGaD
Bezafibrate—PPARD—Gene Expression—PPARG—urinary bladder cancer	4.1e-05	0.000337	CbGpPWpGaD
Bezafibrate—PPARA—Gene Expression—ERCC2—urinary bladder cancer	4.1e-05	0.000337	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.09e-05	0.000336	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—NAT1—urinary bladder cancer	4.06e-05	0.000334	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	4.06e-05	0.000334	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—UGT2B7—urinary bladder cancer	4.05e-05	0.000333	CbGpPWpGaD
Bezafibrate—PPARG—Gene Expression—ESR2—urinary bladder cancer	4.05e-05	0.000333	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—GSTP1—urinary bladder cancer	4.04e-05	0.000331	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—EP300—urinary bladder cancer	4e-05	0.000328	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4e-05	0.000328	CbGpPWpGaD
Bezafibrate—PPARD—Gene Expression—CREBBP—urinary bladder cancer	3.94e-05	0.000324	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—ENO2—urinary bladder cancer	3.93e-05	0.000323	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—HPGDS—urinary bladder cancer	3.93e-05	0.000323	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—MTHFR—urinary bladder cancer	3.93e-05	0.000323	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.9e-05	0.000321	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—SRC—urinary bladder cancer	3.89e-05	0.000319	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—NAT2—urinary bladder cancer	3.88e-05	0.000318	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—GSTT1—urinary bladder cancer	3.82e-05	0.000313	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—RHOA—urinary bladder cancer	3.81e-05	0.000313	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.76e-05	0.000309	CbGpPWpGaD
Bezafibrate—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.76e-05	0.000309	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—TYMS—urinary bladder cancer	3.75e-05	0.000308	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.74e-05	0.000308	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	3.72e-05	0.000305	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—GSTM1—urinary bladder cancer	3.71e-05	0.000305	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—NCOR1—urinary bladder cancer	3.71e-05	0.000305	CbGpPWpGaD
Bezafibrate—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.7e-05	0.000304	CbGpPWpGaD
Bezafibrate—PPARA—Generic Transcription Pathway—MYC—urinary bladder cancer	3.7e-05	0.000304	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—GSTP1—urinary bladder cancer	3.69e-05	0.000303	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—CYP4B1—urinary bladder cancer	3.65e-05	0.0003	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.57e-05	0.000293	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—GPX1—urinary bladder cancer	3.55e-05	0.000292	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—ERBB2—urinary bladder cancer	3.52e-05	0.000289	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—ERCC2—urinary bladder cancer	3.49e-05	0.000286	CbGpPWpGaD
Bezafibrate—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.45e-05	0.000283	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—SLC19A1—urinary bladder cancer	3.45e-05	0.000283	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—TYMS—urinary bladder cancer	3.43e-05	0.000282	CbGpPWpGaD
Bezafibrate—PPARA—Gene Expression—ESR1—urinary bladder cancer	3.43e-05	0.000281	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—EGFR—urinary bladder cancer	3.41e-05	0.00028	CbGpPWpGaD
Bezafibrate—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.4e-05	0.00028	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—NCOR1—urinary bladder cancer	3.39e-05	0.000279	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—GSTM1—urinary bladder cancer	3.39e-05	0.000279	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—PRSS3—urinary bladder cancer	3.36e-05	0.000276	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	3.35e-05	0.000275	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—RRM2—urinary bladder cancer	3.35e-05	0.000275	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—MTHFR—urinary bladder cancer	3.28e-05	0.000269	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—GPX1—urinary bladder cancer	3.25e-05	0.000267	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—TNF—urinary bladder cancer	3.25e-05	0.000267	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—KRAS—urinary bladder cancer	3.22e-05	0.000264	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—PPARG—urinary bladder cancer	3.19e-05	0.000262	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—ERCC2—urinary bladder cancer	3.19e-05	0.000262	CbGpPWpGaD
Bezafibrate—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	3.17e-05	0.00026	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—NQO1—urinary bladder cancer	3.17e-05	0.00026	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	3.16e-05	0.00026	CbGpPWpGaD
Bezafibrate—PPARG—Gene Expression—NCOR1—urinary bladder cancer	3.13e-05	0.000257	CbGpPWpGaD
Bezafibrate—PPARA—Gene Expression—PPARG—urinary bladder cancer	3.13e-05	0.000257	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—HPGDS—urinary bladder cancer	3.1e-05	0.000254	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—ENO2—urinary bladder cancer	3.1e-05	0.000254	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	3.08e-05	0.000253	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.08e-05	0.000253	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.08e-05	0.000253	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—CREBBP—urinary bladder cancer	3.06e-05	0.000252	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—MMP9—urinary bladder cancer	3.02e-05	0.000248	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—GSTT1—urinary bladder cancer	3e-05	0.000247	CbGpPWpGaD
Bezafibrate—PPARA—Gene Expression—CREBBP—urinary bladder cancer	3e-05	0.000247	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—MTHFR—urinary bladder cancer	3e-05	0.000246	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.96e-05	0.000243	CbGpPWpGaD
Bezafibrate—PPARG—Gene Expression—ERCC2—urinary bladder cancer	2.94e-05	0.000241	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—EP300—urinary bladder cancer	2.87e-05	0.000235	CbGpPWpGaD
Bezafibrate—SLCO1B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.81e-05	0.000231	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—SRC—urinary bladder cancer	2.79e-05	0.000229	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—HRAS—urinary bladder cancer	2.74e-05	0.000225	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.69e-05	0.000221	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—TYMP—urinary bladder cancer	2.69e-05	0.000221	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.68e-05	0.00022	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—PPARG—urinary bladder cancer	2.66e-05	0.000218	CbGpPWpGaD
Bezafibrate—PPARG—Generic Transcription Pathway—MYC—urinary bladder cancer	2.65e-05	0.000218	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—GSTP1—urinary bladder cancer	2.65e-05	0.000217	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.58e-05	0.000212	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.56e-05	0.00021	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—CREBBP—urinary bladder cancer	2.55e-05	0.00021	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—PTGS2—urinary bladder cancer	2.51e-05	0.000206	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	2.5e-05	0.000205	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.47e-05	0.000203	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—TYMP—urinary bladder cancer	2.46e-05	0.000202	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—TYMS—urinary bladder cancer	2.46e-05	0.000202	CbGpPWpGaD
Bezafibrate—PPARG—Gene Expression—ESR1—urinary bladder cancer	2.46e-05	0.000202	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—EGFR—urinary bladder cancer	2.44e-05	0.000201	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—NCOR1—urinary bladder cancer	2.43e-05	0.0002	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—GSTM1—urinary bladder cancer	2.43e-05	0.0002	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—PPARG—urinary bladder cancer	2.43e-05	0.0002	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—NAT2—urinary bladder cancer	2.43e-05	0.000199	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.42e-05	0.000199	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.36e-05	0.000194	CbGpPWpGaD
Bezafibrate—PPARD—Gene Expression—MYC—urinary bladder cancer	2.34e-05	0.000192	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—CREBBP—urinary bladder cancer	2.33e-05	0.000192	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—GPX1—urinary bladder cancer	2.33e-05	0.000191	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—TNF—urinary bladder cancer	2.33e-05	0.000191	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—KRAS—urinary bladder cancer	2.31e-05	0.000189	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.3e-05	0.000189	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—ERCC2—urinary bladder cancer	2.29e-05	0.000188	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—NAT2—urinary bladder cancer	2.23e-05	0.000183	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—PTEN—urinary bladder cancer	2.19e-05	0.00018	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.18e-05	0.000179	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.18e-05	0.000179	CbGpPWpGaD
Bezafibrate—PPARG—Gene Expression—CREBBP—urinary bladder cancer	2.15e-05	0.000177	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—MTHFR—urinary bladder cancer	2.15e-05	0.000176	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.11e-05	0.000174	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—RRM2—urinary bladder cancer	2.1e-05	0.000172	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—PTGS2—urinary bladder cancer	2.09e-05	0.000172	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—EP300—urinary bladder cancer	2.09e-05	0.000171	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	2.08e-05	0.000171	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.02e-05	0.000165	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2e-05	0.000164	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—HRAS—urinary bladder cancer	1.96e-05	0.000161	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	1.94e-05	0.000159	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—ENO2—urinary bladder cancer	1.94e-05	0.000159	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	1.94e-05	0.000159	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.93e-05	0.000159	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.92e-05	0.000158	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	1.91e-05	0.000157	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	1.91e-05	0.000157	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—PTGS2—urinary bladder cancer	1.91e-05	0.000157	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	1.88e-05	0.000155	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.85e-05	0.000152	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	1.83e-05	0.000151	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—PTEN—urinary bladder cancer	1.82e-05	0.00015	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	1.8e-05	0.000148	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.8e-05	0.000148	CbGpPWpGaD
Bezafibrate—PPARA—Gene Expression—MYC—urinary bladder cancer	1.78e-05	0.000146	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.78e-05	0.000146	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.78e-05	0.000146	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.77e-05	0.000145	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—EP300—urinary bladder cancer	1.74e-05	0.000143	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.73e-05	0.000142	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.7e-05	0.00014	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.7e-05	0.000139	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	1.69e-05	0.000139	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—CREBBP—urinary bladder cancer	1.67e-05	0.000137	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—PTEN—urinary bladder cancer	1.67e-05	0.000137	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.65e-05	0.000136	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—EP300—urinary bladder cancer	1.59e-05	0.000131	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—NQO1—urinary bladder cancer	1.57e-05	0.000129	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.52e-05	0.000125	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.43e-05	0.000118	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.39e-05	0.000114	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	1.37e-05	0.000113	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—PTGS2—urinary bladder cancer	1.37e-05	0.000113	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.32e-05	0.000109	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.32e-05	0.000109	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	1.32e-05	0.000108	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	1.31e-05	0.000107	CbGpPWpGaD
Bezafibrate—PPARG—Gene Expression—MYC—urinary bladder cancer	1.28e-05	0.000105	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.26e-05	0.000104	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.21e-05	9.97e-05	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—TYMS—urinary bladder cancer	1.21e-05	9.97e-05	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	1.2e-05	9.85e-05	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	1.2e-05	9.85e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.2e-05	9.83e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.2e-05	9.82e-05	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—PTEN—urinary bladder cancer	1.2e-05	9.81e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.16e-05	9.51e-05	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—GPX1—urinary bladder cancer	1.15e-05	9.43e-05	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—EP300—urinary bladder cancer	1.14e-05	9.36e-05	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	1.13e-05	9.26e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.11e-05	9.14e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.1e-05	9.03e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.1e-05	9.03e-05	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	1.08e-05	8.86e-05	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	1.06e-05	8.71e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.05e-05	8.65e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.03e-05	8.49e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.03e-05	8.47e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	9.72e-06	7.98e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	9.56e-06	7.85e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—ENO2—urinary bladder cancer	9.56e-06	7.85e-05	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	9.41e-06	7.73e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	9.27e-06	7.61e-05	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—EP300—urinary bladder cancer	8.97e-06	7.37e-05	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—PPARG—urinary bladder cancer	8.6e-06	7.06e-05	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	8.26e-06	6.78e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—PPARG—urinary bladder cancer	7.88e-06	6.47e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.7e-06	6.33e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	7.57e-06	6.22e-05	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	6.76e-06	5.55e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.42e-06	5.28e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	6.2e-06	5.09e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.97e-06	4.9e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.9e-06	4.85e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.9e-06	4.85e-05	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—PTEN—urinary bladder cancer	5.9e-06	4.84e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.65e-06	4.64e-05	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—EP300—urinary bladder cancer	5.62e-06	4.62e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.55e-06	4.56e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—PTEN—urinary bladder cancer	5.41e-06	4.44e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.22e-06	4.28e-05	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—EP300—urinary bladder cancer	5.16e-06	4.24e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.23e-06	3.47e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.06e-06	3.34e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.33e-06	2.73e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.9e-06	2.38e-05	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.77e-06	2.27e-05	CbGpPWpGaD
